Page last updated: 2024-11-03

propranolol and Erythrocytosis

propranolol has been researched along with Erythrocytosis in 6 studies

Propranolol: A widely used non-cardioselective beta-adrenergic antagonist. Propranolol has been used for MYOCARDIAL INFARCTION; ARRHYTHMIA; ANGINA PECTORIS; HYPERTENSION; HYPERTHYROIDISM; MIGRAINE; PHEOCHROMOCYTOMA; and ANXIETY but adverse effects instigate replacement by newer drugs.
propranolol : A propanolamine that is propan-2-ol substituted by a propan-2-ylamino group at position 1 and a naphthalen-1-yloxy group at position 3.

Research Excerpts

ExcerptRelevanceReference
" D-Propranolol and metoprolol did not reduce hypoxia-induced right ventricular hypertrophy or polycythemia."3.66Chronic propranolol treatment blunts right ventricular hypertrophy in rats at high altitude. ( McMurtry, IF; Reeves, JT; Voelkel, NF, 1980)
"The isoproterenol effect was blocked by an agent with beta 2 receptor specificity (butoxamine), and L-isomeric configuration (L-propranolol)."1.27Adrenergic modulation of erythropoiesis: in vitro studies of colony-forming cells in normal and polycythaemic man. ( Adamson, JW; Mladenovic, J, 1984)
"Terbutaline did not produce a significant effect upon blood gases or blood pH."1.26Effects of terbutaline, a synthetic beta adrenoceptor agonist, on in vivo erythropoietin production. ( Fisher, JW; Gross, DM, 1978)

Research

Studies (6)

TimeframeStudies, this research(%)All Research%
pre-19904 (66.67)18.7374
1990's1 (16.67)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (16.67)2.80

Authors

AuthorsStudies
Tymko, MM1
Lawley, JS1
Ainslie, PN1
Hansen, AB1
Hofstaetter, F1
Rainer, S1
Amin, S1
Moralez, G1
Gasho, C1
Vizcardo-Galindo, G1
Bermudez, D1
Villafuerte, FC1
Hearon, CM1
Voelkel, NF1
McMurtry, IF1
Reeves, JT2
Mladenovic, J1
Adamson, JW1
Grover, RF1
Selland, MA1
McCullough, RG1
Dahms, TE1
Wolfel, EE1
Butterfield, GE1
Greenleaf, JE1
Gross, DM1
Fisher, JW1
Pruyn, SC1
Phelan, JP1
Buchanan, GC1

Clinical Trials (2)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Propranolol Versus Placebo for Induction of Labor in Nulliparous Patients: a Double-blind Randomized Controlled Trial[NCT03348683]Phase 2240 participants (Actual)Interventional2017-12-11Completed
Propranolol for Prolonged Labor: A Randomized Controlled Trial (PRO-Labor Trial)[NCT04741698]Phase 180 participants (Actual)Interventional2021-07-27Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Duration of Latent

Time of latent labor defined as <6cm of cervical dilation. (NCT03348683)
Timeframe: average of 24 hours

Interventionhours (Mean)
Propranolol11.0
Placebo11.2

Number of Fetus With Fetal Bradycardia

Count of fetus with fetal bradycardia (<110bpm for >10 minutes within 30 minutes of study drug administration) (NCT03348683)
Timeframe: 30 minutes from drug administration

InterventionParticipants (Count of Participants)
Propranolol1
Placebo0

Number of Fetus With Heart Rate Decelerations

Count of fetus with fetal heart rate decelerations within 30 minutes of study drug administration (NCT03348683)
Timeframe: 30 minutes from drug administration

InterventionParticipants (Count of Participants)
Propranolol15
Placebo13

Number of Neonates With Hypoglycemia

"Neonatal outcome - Number of neonates with hypoglycemia (blood glucose <50).~This population includes only the neonates who had heelsticks to check their blood glucose, which is not a universal practice and was not required by the protocol or IRB. The neonates included were those who met the nursery's risk-based protocol to check blood glucose after birth (ex: infants of diabetic mothers, fetal growth restriction, macrosomia, or symptoms suggestive of hypoglycemia)" (NCT03348683)
Timeframe: Day 1

InterventionParticipants (Count of Participants)
Propranolol11
Placebo8

Number of Neonates With Neonatal Outcome Composite Score = 1

"Composite neonatal outcome score was for any of the following morbidity: Neonatal Intensive Care Unit (NICU) admission, respiratory support (CPAP, nasal cannula, intubation), culture proven sepsis, radiographically proven intracranial hemorrhage, necrotizing enterocolitis, hypoglycemia (for those infants who had sugar checked), and neonatal death.~The composite score was computed as a score of 1 for any indication of neonatal morbidity - neonates who experienced at least one morbidity and the components are given equal weights. Patients who had no evidence of the predefined neonatal morbidities are subsequently given a score of 0. The minimum is 0 and maximum is 1." (NCT03348683)
Timeframe: Day 1

InterventionParticipants (Count of Participants)
Propranolol21
Placebo28

Number of Participants With Maternal Morbidity Composite Score = 1

"Composite maternal morbidity score consists of a count of postpartum hemorrhage, transfusion, hysterectomy, placental abruption, chorioamnionitis, shoulder dystocia, episiotomy, higher order laceration, and ICU admission.~The composite score was computed as a score of 1 for any indication of maternal morbidity, that is the participant experienced at least one maternal morbidity, and the components are given equal weights. Participants who had no evidence of the predefined maternal morbidities are subsequently given a score of 0. The minimum is 0 and maximum is 1." (NCT03348683)
Timeframe: average of 24 hours

InterventionParticipants (Count of Participants)
Propranolol35
Placebo49

Number of Participants With Postpartum Hemorrhage

Greater than 500cc of blood expelled during a vaginal delivery or greater than 1000cc of blood expelled during a cesarean section (NCT03348683)
Timeframe: 30 minutes from drug administration

InterventionParticipants (Count of Participants)
Propranolol15
Placebo26

Time From Beginning of Induction to Delivery

The time of induction (based on time of foley balloon placement for cervical ripening or misoprostol administration) to the time of delivery of the infant. (NCT03348683)
Timeframe: average of 24 hours

Interventionhours (Mean)
Propranolol13.8
Placebo14.3

Number of Participants With Various Mode of Delivery

Number of various mode of delivery - count of Vaginal delivery, vacuum assisted vaginal delivery, forceps assisted vaginal delivery, cesarean section (NCT03348683)
Timeframe: average of 24 hours

,
InterventionParticipants (Count of Participants)
Spontaneous vaginal deliveryVacuum assisted vaginal deliveryForceps assisted vaginal deliveryCesarean section
Placebo6110840
Propranolol643846

Other Studies

6 other studies available for propranolol and Erythrocytosis

ArticleYear
Global Reach 2018 Heightened α-Adrenergic Signaling Impairs Endothelial Function During Chronic Exposure to Hypobaric Hypoxia.
    Circulation research, 2020, 07-03, Volume: 127, Issue:2

    Topics: Acetylcholine; Adaptation, Physiological; Adrenergic Agents; Adult; Altitude; Altitude Sickness; Blo

2020
Chronic propranolol treatment blunts right ventricular hypertrophy in rats at high altitude.
    Journal of applied physiology: respiratory, environmental and exercise physiology, 1980, Volume: 48, Issue:3

    Topics: Adaptation, Physiological; Altitude; Animals; Cardiomegaly; Hypoxia; Male; Metoprolol; Polycythemia;

1980
Adrenergic modulation of erythropoiesis: in vitro studies of colony-forming cells in normal and polycythaemic man.
    British journal of haematology, 1984, Volume: 56, Issue:2

    Topics: Butoxamine; Carbachol; Cells, Cultured; Colony-Forming Units Assay; Dose-Response Relationship, Drug

1984
Beta-adrenergic blockade does not prevent polycythemia or decrease in plasma volume in men at 4300 m altitude.
    European journal of applied physiology and occupational physiology, 1998, Volume: 77, Issue:3

    Topics: Adrenergic beta-Antagonists; Adult; Altitude; Blood Volume; Erythropoiesis; Erythropoietin; Humans;

1998
Effects of terbutaline, a synthetic beta adrenoceptor agonist, on in vivo erythropoietin production.
    Archives internationales de pharmacodynamie et de therapie, 1978, Volume: 236, Issue:2

    Topics: Animals; Blood Gas Analysis; Blood Pressure; Epinephrine; Erythropoiesis; Erythropoietin; Female; Hy

1978
Long-term propranolol therapy in pregnancy: maternal and fetal outcome.
    American journal of obstetrics and gynecology, 1979, Oct-15, Volume: 135, Issue:4

    Topics: Asphyxia Neonatorum; Bradycardia; Female; Fetal Growth Retardation; Fetus; Humans; Hypertension; Hyp

1979
Long-term propranolol therapy in pregnancy: maternal and fetal outcome.
    American journal of obstetrics and gynecology, 1979, Oct-15, Volume: 135, Issue:4

    Topics: Asphyxia Neonatorum; Bradycardia; Female; Fetal Growth Retardation; Fetus; Humans; Hypertension; Hyp

1979
Long-term propranolol therapy in pregnancy: maternal and fetal outcome.
    American journal of obstetrics and gynecology, 1979, Oct-15, Volume: 135, Issue:4

    Topics: Asphyxia Neonatorum; Bradycardia; Female; Fetal Growth Retardation; Fetus; Humans; Hypertension; Hyp

1979
Long-term propranolol therapy in pregnancy: maternal and fetal outcome.
    American journal of obstetrics and gynecology, 1979, Oct-15, Volume: 135, Issue:4

    Topics: Asphyxia Neonatorum; Bradycardia; Female; Fetal Growth Retardation; Fetus; Humans; Hypertension; Hyp

1979